Biostrategy Partners

Pharma germinator, a program designed to facilitate industry-academic collaborations through a customized sponsored research process, expanded to include additional corporate Partners and research institutions. In addition to the long-standing partnership with janssen research & development, Biostrategy Partners entered into contracts with depuy synthes and glaxosmithkiline. The wistar institute of anatomy and biology and the university of the sciences joined as new members of Biostrategy Partners. These new institutions expand the number of research institutions to six, joining the lankenau institute of medical research, Pennsylvania state university, temple university, thomas jefferson university, and the wistar institute of anatomy and biology. Based on the new corporate contracts and expanded membership, Biostrategy Partners launched new pharma germinator grant rounds in this fiscal year with the potential to fund up to 13 technology advancement projects in the next fiscal year.biostrategy partner'Partners's practical knowledge series (pks) of educational events provides practical and tactical content, delivered by experts, with a focus on translational science and the commercialization of technologies arising from member universities and research institutions. Pks broadcasts all content to the members of Biostrategy Partners, which expanded from four institutions to six in this fiscal year.

Biostrategy partner'Partners's practical knowledge series (pks) of educational events provides practical and tactical content, delivered by experts, with a focus on translational science and the commercialization of technologies arising from member universities and research institutions. Pks broadcasts all content to the members of Biostrategy Partners, which expanded from four institutions to six in this fiscal year.